Unicycive Therapeutics, Inc.UNCYEarnings & Financial Report
Nasdaq
UNCY Q4 2023 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-6.3M
Net Profit
$-7.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.11
Unicycive Therapeutics, Inc. Q4 2023 Financial Summary
Unicycive Therapeutics, Inc. reported revenue of $0 for Q4 2023, with a net profit of $-7.8M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 2023 |
Unicycive Therapeutics, Inc. Annual Revenue by Year
Unicycive Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $675.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $675.0K |
Income Statement
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|
| Revenue | $951000 | $675000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|
| Assets | $10.2M | $27.2M | $22.9M | $19.4M | $14.2M |
| Liabilities | $5.6M | $16.7M | $16.1M | $16.0M | $18.0M |
| Equity | $4.6M | $-15.1M | $-19.4M | $3.4M | $-3.8M |
Cash Flow
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-3.6M | $-3.9M | $-5.5M | $-4.4M | $-4.4M |